TGFβ1-IN-2

CAS No. 2700263-58-5

TGFβ1-IN-2( —— )

Catalog No. M36620 CAS No. 2700263-58-5

TGFβ1-IN-2, a derivative of diarylacylhydrazones, effectively inhibits fibroblast activation and proliferation and holds potential for idiopathic pulmonary fibrosis (IPF) research .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 603 Get Quote
5MG 922 Get Quote
10MG 1121 Get Quote
25MG 1454 Get Quote
50MG 1822 Get Quote
100MG 2250 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    TGFβ1-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    TGFβ1-IN-2, a derivative of diarylacylhydrazones, effectively inhibits fibroblast activation and proliferation and holds potential for idiopathic pulmonary fibrosis (IPF) research .
  • Description
    TGFβ1-IN-2, a derivative of diarylacylhydrazones, effectively inhibits fibroblast activation and proliferation and holds potential for idiopathic pulmonary fibrosis (IPF) research .
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2700263-58-5
  • Formula Weight
    458.57
  • Molecular Formula
    C23H30N4O4S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(=NNC(=O)C1=CC=C(OCCCCCCN2CCCCC2)C=C1)C=3SC(N(=O)=O)=CC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • WSP-1

    WSP-1 is a selective 2-pyridyl disulfide fluorescent probe for hydrogen sulfide detection and bioimaging.

  • UK 088800

    UK 088800 is a bioacitve chemical.

  • Enoblituzumab

    Enoblituzumab is a humanized IgG1 κmab monoclonal antibody that recognizes human B7-H3 protein and can be used to study solid tumors such as non-small cell lung cancer (NSCLC).